FIG 2.

Antifungal susceptibility pattern of C. auris clinical isolates from New Jersey, 2017 to 2020. (A) Percent C. auris resistant isolates to antifungals for which CDC tentative MIC breakpoint (CDC-BP) are available. All isolates were resistant to fluconazole (FLC) followed by amphotericin B (AMB), while none showed resistance to echinocandins. (B) Percent C. auris non-wild-type isolates based on epidemiological cutoff values (ECV). A higher percentage of C. auris isolates was non-wild-type to posaconazole (POS) compared with the other azoles.